tbuckley/cabot-search huggingface dataset:
Chronic Fatigue-Reply
Authors: Kurt Kroenke
Journal: JAMA (1989)

<h3>In Reply.—</h3> Dr Jackson and Dr Meth share a common concern—namely, that so few of the patients in our study were treated with antidepressants. First, our patients had screening psychometric scores "suggestive of depression," not clinically diagnosed major affective disorders. Second, our study was purposely designed not as a clinical trial, but rather as a prospective examination of the characteristics and natural history of fatigued individuals. The patients enrolled in our study continued to receive their medical care from their primary physicians rather than the investigators. In only four instances did the primary care physician elect to use antidepressant medication. This provided a unique opportunity to study the outcome of chronic fatigue after one year of follow-up. The fact that 28% of patients improved during the course of the year provides important baseline data for future therapeutic trials. Had selected patients been offered antidepressant medication simply on the basis of
Affinity of fibronectin to collagens of different genetic types and to fibrinogen.
Authors: E Engvall, E Ruoslahti, E J Miller
Journal: The Journal of Experimental Medicine (1978)

Fibronectin, a fibroblast surface protein, was purified from human and chicken plasma and extracts of cultured chicken fibroblasts with affinity chromatography on gelatin coupled to Sepharose particles. A fibronectin-like protein was also isolated from the plasma of Torpedo fish. The collagen binding properties of fibronectin were studied with several genetically distinct collagens. Heat denatured types I, II, and III collagens were equal in their binding capacity and more active than the native collagens or A and B chains. Native type III collagen was more active than the other native collagens. Human and chicken fibronectins showed approximately the same pattern of specificity. Identical specificities were shown by the plasma and fibroblast forms of chicken fibronectin. Two cyanogen bromide peptides of the collagen alpha1 (II) chain, CB8 and CB12, derived from different parts of the chain, were active in fibronectin binding. A polymer of the tripeptide pro-gly-pro, and polyproline were inactive. Fibronectin also binds to fibrinogen and fibrin. Comparison of this binding to collagen binding showed that fibrinogen inhibited binding of fibronectin to collagen, but was less active than native collagen. Two other fibrous proteins, tropoelastin and keratin, did not bind fibronectin. The binding of fibronectin to fibrinogen was inhibited by collagen and incorporation of fibronectin into blood clot in the cold was inhibited by gelatin. These results suggest that the binding of fibronectin to collagen and fibrinogen depends on the same binding site in the fibronectin molecule. It is proposed that cell surface fibronectin mediates attachment of cells to the collagenous extracellular matrix and to a temporary fibrin matrix in a wound.
OBSTRUCTION OF THE BOWELS FROM MECKEL'S DIVERTICULUM.
Authors: JAMES E. MOORE
Journal: JAMA (1902)

Notwithstanding the fact that modern surgery has brought the mortality rate from obstruction of the bowels down from 95 to 60 per cent., it continues to be one of the most desperate conditions the surgeon is called on to treat, and every experience and observation which will help us to reduce this mortality still lower should be welcome. This subject has been so well written up by Fitz,<sup>1</sup>Kammerer,<sup>2</sup>and Halsted,<sup>3</sup>that it is necessary to dwell but very briefly on the history and pathologic anatomy as an introduction to the report of my three cases. Meckel's diverticulum is a diverticulum of the ileum and is a portion of the unobliterated omphalo-mesenteric canal of fetal life. Although it bears Meckel's name, it was first described by Ruysch in 1701, while Meckel's article did not appear until 1809. From the fourth to the sixth week of fetal life
Abstract 804: The impact of aromatase inhibitor therapy on ER co-regulator expression and interaction
Authors: Ryan J. Bourgo, Geoffrey L. Greene
Journal: Cancer Research (2012)

Abstract Estrogen receptor alpha (ERα) is a member of the nuclear receptor family and is currently recognized as the most defining metric in breast cancer diagnosis and treatment. Roughly 70% of all breast cancer patients present with ERα-positive, hormone sensitive disease, and the majority of these women are post-menopausal. Because post-menopausal women require the aromatase enzyme for estrogen synthesis, the first line of treatment for these patients is aromatase inhibitor (AI) therapy. Despite the number of women whose primary disease responds positively, a significant fraction of patients fail to gain any clinical benefit due to intrinsic resistance, or eventually relapse due to acquired resistance to AI therapy. Currently, the biochemical changes underlying both intrinsic and acquired resistance to AI therapy is yet unknown; thus, resistance to AI therapy remains a significant clinical obstacle for a large fraction of breast cancer patients. Here, we investigate the impact of ERα co-regulators on intrinsic and acquired AI resistance in breast cancer. In vitro administration of testosterone to wild-type MCF-7, T47-D, or ZR75-1 cells is capable of offering a significant ERα-dependent proliferative advantage, suggesting an active role for aromatase in these cells. Interestingly, aromatase inhibitor (Anastrazole) treatment of these cells alters the expression of specific ERα co-regulators independent of ligand. Furthermore, interaction between ERα and individual co-regulators is altered after treatment with estradiol or testosterone, and is impacted by Anastrazole treatment acutely. While these findings are preliminary, further investigation is on-going and promises to provide critical insight into the contributions of ERα co-regulators to the short- and long-term response to AI-mediated estrogen deprivation, as well as establish the alterations in ERα-mediated promoter occupancy and gene regulation that contribute to intrinsic and acquired AI resistance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 804. doi:1538-7445.AM2012-804
Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice
Authors: Ya-Fei Xu, Yong-Jie Zhang, Wen-Lang Lin, Xiangkun Cao, Caroline Stetler, Dennis W Dickson, Jada Lewis, Leonard Petrucelli
Journal: Molecular Neurodegeneration (2011)

Abstract Background Abnormal distribution, modification and aggregation of transactivation response DNA-binding protein 43 (TDP-43) are the hallmarks of multiple neurodegenerative diseases, especially frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS). Researchers have identified 44 mutations in the TARDBP gene that encode TDP-43 as causative for cases of sporadic and familial ALS http://www.molgen.ua.ac.be/FTDMutations/ . Certain mutant forms of TDP-43, such as M337V, are associated with increased low molecular weight (LMW) fragments compared to wild-type (WT) TDP-43 and cause neuronal apoptosis and developmental delay in chick embryos. Such findings support a direct link between altered TDP-43 function and neurodegeneration. Results To explore the pathogenic properties of the M337V mutation, we generated and characterized two mouse lines expressing human TDP-43 (hTDP-43 M337V ) carrying this mutation. hTDP-43 M337V was expressed primarily in the nuclei of neurons in the brain and spinal cord, and intranuclear and cytoplasmic phosphorylated TDP-43 aggregates were frequently detected. The levels of TDP-43 LMW products of ~25 kDa and ~35 kDa species were also increased in the transgenic mice. Moreover, overexpression of hTDP-43 M337V dramatically down regulated the levels of mouse TDP-43 (mTDP-43) protein and RNA, indicating TDP-43 levels are tightly controlled in mammalian systems. TDP-43 M337V mice displayed reactive gliosis, widespread ubiquitination, chromatolysis, gait abnormalities, and early lethality. Abnormal cytoplasmic mitochondrial aggregates and abnormal phosphorylated tau were also detected in the mice. Conclusion Our novel TDP-43 M337V mouse model indicates that overexpression of hTDP-43 M337V alone is toxic in vivo . Because overexpression of hTDP-43 in wild-type TDP-43 and TDP-43 M337V mouse models produces similar phenotypes, the mechanisms causing pathogenesis in the mutant model remain unknown. However, our results suggest that overexpression of the hTDP-43 M337V can cause neuronal dysfunction due to its effect on a number of cell organelles and proteins, such as mitochondria and TDP-43, that are critical for neuronal activity. The mutant model will serve as a valuable tool in the development of future studies designed to uncover pathways associated with TDP-43 neurotoxicity and the precise roles TDP-43 RNA targets play in neurodegeneration.
Effect of Total Dose Infusion of Iron-dextran on Iron, Folate, and Vitamin B12 Nutrition in Postpartum Anaemia
Authors: J. Metz, T. Edelstein, M. Divaris, S. S. Zail
Journal: BMJ (1967)

and that increasing refinement of chemical and other investigations may in time render biopsy obsolete also in many cases of neurolipidosis.Pneumoencephalography was of no value in selecting cases for rectal biopsy, since it showed cerebral atrophy with equal frequency in patients whose biopsies later did and did not show diagnostic changes.No diagnostic abnormalities were found on rectal biopsy in patients without dementia, a positive family history of relevant disease or other features pointing strongly towards a specific neurological condition.We thank the physicians and surgeons of the Hospital for Sick Children, Great Ormond Street, for permission to publish details of patients in their care. REFERENCES
An immunofluorescence study of pityriasis lichenoides
Authors: ROGER CLAYTON, GERALD HAFFENDEN
Journal: British Journal of Dermatology (1978)

In a study of 27 patients with pityriasis lichenoides IgM and C3 have been observed on direct immunofluorescence of fresh lesions. Other immunoglobulins and complement components were not observed. Immunofluorescence was seen in 31 (72%) of 43 fresh lesions. It occurred in the walls of superficial dermal vessels and along the dermal-epidermal junction. This pattern of immunofluorescence appears to be characteristic of the disease. Uninvolved skin showed the immunofluorescence less frequently and old scaly lesions none. The concept that pityriasis lichenoides is an immune complex disorder is discussed.
The mechanism of cell-damaging reactive oxygen generation by colloidal fullerenes
Authors: Zoran Markovic, Biljana Todorovic-Markovic, Duska Kleut, Nadezda Nikolic, Sanja Vranjes-Djuric, Maja Misirkic, Ljubica Vucicevic, Kristina Janjetovic, Aleksandra Isakovic, Ljubica Harhaji, Branka Babic-Stojic, Miroslav Dramicanin, Vladimir Trajkovic
Journal: Biomaterials (2007)
Detection of the antigenicity of the d-dimer of cross linked fibrin in the glomerulus by plasmin treatment
Authors: Takahiko Ono, Kazuro Kanatsu, Satoshi Ueda, Takahiko Matsuo, Takashi Kuwahara, Chika Onoe, Hiroyuki Nagai, Eri Muso, Shigetake Sasayama
Journal: Kidney International (1994)
Sweat gland function in Sjögren's syndrome.
Authors: L.E Hart, D Caspi, R.G Hull, A Begant, J Beacham, G.R Hughes
Journal: Annals of the Rheumatic Diseases (1986)

psoriatic arthritis, and compare this with the observed frequency in patients with rheumatoid arthritis.Sera from 14 patients with psoriatic arthritis and 13 patients with rheumatoid factor positive arthritis, fulfilling American Rheumatism Association criteria for definite or classical rheumatoid arthritis, were examined for the presence of antikeratin antibodies using the method described by Young et al.3 Estimation of rheumatoid factor titre was carried out by an enzyme linked immunosorbent assay.None of the 14 patients with psoriatic arthritis had identifiable antikeratin antibodies or significant levels of rheumatoid factor.Of the patients with rheumatoid disease, four of 13 were positive for antikeratin antibodies including, most notably, the two patients with highest titres of rheumatoid factor (336 and 304 IU/I respectively).These results are in accord with the finding of both a high specificity of antikeratin antibodies for rheumatoid arthri- tis, and the observed correlation between antibody level and disease activity;4 they certainly do not support a role for them in the pathogenesis of psoriatic arthritis.
Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia
Authors: Andrea Meinhardt, Birgit Burkhardt, Martin Zimmermann, Arndt Borkhardt, Udo Kontny, Thomas Klingebiel, Frank Berthold, Gritta Janka-Schaub, Christoph Klein, Edita Kabickova, Wolfram Klapper, Andishe Attarbaschi, Martin Schrappe, Alfred Reiter
Journal: Journal of Clinical Oncology (2010)

The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined. We conducted a phase II window study to examine activity and tolerability of rituximab in newly diagnosed pediatric B-NHL.Patients younger than age 19 years with CD20(+) B-NHL with at least one measurable site were eligible. Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1; concomitant therapy consisted of rasburicase, intrathecally (IT) triple drug (methotrexate, cytarabine, and prednisolone) on days 1 and 3 for CNS-positive patients and steroids only for anaphylaxis. Response criterion was the product of the two largest perpendicular diameters of one to three lesions and/or the percentage of blasts in bone marrow (BM) or peripheral blood (PB) within 24 hours before rituximab and on day 5. Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites. Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity.From April 2004 to August 2008, 136 patients were enrolled. National Cancer Institute Common Toxicity Criteria 3/4 toxicities attributable to rituximab were general condition, 15%; fatigue, 13%; anaphylaxis, 7%; infection, 3%; glutamic-oxaloacetic transaminase/glutamic-pyruvic transaminase, 8%; no capillary leakage; and no toxic death. Forty-nine patients were not evaluable for response because of withdrawal from the study (n = 16), IT therapy in CNS-negative patients (n = 8), corticosteroid treatment (n = 3), technical inadequacy of response evaluation (n = 21), or no evaluable lesion (n = 1). Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma. A response was more frequently observed in BM (12 of 18) compared with solid tumor lesions (36 of 108; P = .007).Rituximab is active as a single-agent in pediatric B-NHL even though the RR was lower than requested in the phase II plan.
Cat-scratch Disease and Bacillary Angiomatosis
Authors: Jordan W. Tappero
Journal: JAMA (1991)

<h3>To the Editor.</h3> —We found the article by Dr Holley<sup>1</sup>on successful ciprofloxacin treatment of cat-scratch disease (CSD) to be very interesting. However, we believe that it is important to make a distinction between the diagnosis and treatment of CSD and the disease bacillary angiomatosis (BA), most significantly because we have identified four immunocompromised patients with BA who did not appear to respond to ciprofloxacin treatment. The five patients treated by Holley were apparently immunocompetent and had classic CSD (although no organisms were demonstrated). The author queries whether ciprofloxacin might prove effective and curative in immunocompromised patients, and briefly comments on antibiotic therapies reported in the literature, although several of these cases had skin lesions representative of BA in immunocompromised patients.<sup>2,3</sup>Our four patients with biopsyproven BA, summarized in the Table, either developed BA while taking ciprofloxacin (patient 1) or failed to show any improvement during a 6
CARBON-DIOXIDE NARCOSIS THERAPY
Authors: JOSEF A. KINDWALL
Journal: American Journal of Psychiatry (1949)

The use of carbon dioxide narcosis therapy is reported using 75 cases as a base for discussion. Statistical analysis is not attempted, but the reactions of some patients are described. The experience of 2 of the investigators who took a long series of the treatments is reported. The variation in effect in different patients at different times is emphasized; so also is the value of the method in promoting rapport, insight, relaxation, and management of the patient. The individual treatment is compared to a brief, elective, controllable toxic psychosis.
Self-deception: A paradox revisited
Authors: Albert Bandura
Journal: Behavioral and Brain Sciences (2011)

Abstract A major challenge to von Hippel &amp; Trivers's evolutionary analysis of self-deception is the paradox that one cannot deceive oneself into believing something while simultaneously knowing it to be false. The authors use biased information seeking and processing as evidence that individuals knowingly convince themselves of the truth of their falsehood. Acting in ways that keep one uninformed about unwanted information is self-deception. Acting in selectively biasing and misinforming ways is self-bias.
High F-18 FDG Uptake in a Low-Grade Supratentorial Ganglioglioma
Authors: PHILIPP T. MEYER, UWE SPETZGER, HARALD D. MUELLER, THOMAS ZEGGEL, OSAMA SABRI, MATHIAS SCHRECKENBERGER
Journal: Clinical Nuclear Medicine (2000)

Purpose Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (F-18 FDG) is used for the noninvasive monitoring and grading of primary brain tumors. Here the FDG uptake is positively correlated with the malignant extent of the lesion and thereby negatively correlated with patient survival. Little is known about the FDG PET features of primary brain tumors in children, such as mixed neuronal-glial tumors. Methods The authors describe a 13-year-old boy who had partial complex seizures since early childhood caused by a brain tumor in the left temporal lobe. Results Magnetic resonance and computed tomographic examinations yielded uncharacteristic results: mixed density, marked calcifications, little contrast enhancement, a nearly absent mass effect, and no edema. The FDG PET scan revealed a large hypermetabolic tumor, with a tumor: contralateral gray matter FDG uptake ratio of 1.45. In contrast to this intense hypermetabolism, the pathologic analysis after gross total resection revealed a low-grade ganglioglioma (WHO grade I), which is usually associated with an excellent prognosis. Conclusions Mixed neuronal-glial tumors such as gangliogliomas must be considered in making differential diagnoses by judging hypermetabolic FDG PET scans in young patients with brain tumors in the presence of uncharacteristic imaging features.
Linear morphoea with spontaneous fractures
Authors: M.V. Barrera Vigo, A. Torrelo, A. Hernandez, G. Gonzalez
Journal: British Journal of Dermatology (2008)

Journal Article Linear morphoea with spontaneous fractures Get access M.V. Barrera Vigo, M.V. Barrera Vigo Department of Dermatology, Hospital Niño Jesus, Menendez Pelayo 65, Madrid 28034, Spain E‐mail: atorrelo@aedv.es Search for other works by this author on: Oxford Academic Google Scholar A. Torrelo, A. Torrelo Department of Dermatology, Hospital Niño Jesus, Menendez Pelayo 65, Madrid 28034, Spain E‐mail: atorrelo@aedv.es Search for other works by this author on: Oxford Academic Google Scholar A. Hernandez, A. Hernandez Department of Dermatology, Hospital Niño Jesus, Menendez Pelayo 65, Madrid 28034, Spain E‐mail: atorrelo@aedv.es Search for other works by this author on: Oxford Academic Google Scholar G. Gonzalez G. Gonzalez Department of Dermatology, Hospital Niño Jesus, Menendez Pelayo 65, Madrid 28034, Spain E‐mail: atorrelo@aedv.es Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 158, Issue 4, 1 April 2008, Pages 852–853, https://doi.org/10.1111/j.1365-2133.2007.08422.x Published: 01 April 2008
Patients With Nondysplastic Barrett's Esophagus Have Low Risks for Developing Dysplasia or Esophageal Adenocarcinoma
Authors: Sachin Wani, Gary Falk, Matthew Hall, Srinivas Gaddam, Amy Wang, Neil Gupta, Mandeep Singh, Vikas Singh, Keng–Yu Chuang, Vikram Boolchand, Hemanth Gavini, John Kuczynski, Priti Sud, Savio Reddymasu, Ajay Bansal, Amit Rastogi, Sharad C. Mathur, Patrick Young, Brooks Cash, David A. Lieberman, Richard E. Sampliner, Prateek Sharma
Journal: Clinical Gastroenterology and Hepatology (2010)
New buildings not needed for polyclinics, says King’s Fund
Authors: Zosia Kmietowicz
Journal: BMJ (2008)

Local NHS organisations should be given the freedom from Whitehall to implement large health centres or “polyclinics” in the way that they think will best serve their population, the head of one of the United Kingdom’s leading organisations for research into healthcare policy has said.

In particular, Niall Dickson, chief executive of the King’s Fund, said that local health bodies should not be required to erect new buildings to house polyclinics when other ways of implementing the policy will work. 

Mr Dickson acknowledged that advances in technology, changes in patients’ expectations, and …
Noninvasive Programmed Ventricular Stimulation Early After Ventricular Tachycardia Ablation to Predict Risk of Late Recurrence
Authors: David S. Frankel, Stavros E. Mountantonakis, Erica S. Zado, Elad Anter, Rupa Bala, Joshua M. Cooper, Rajat Deo, Sanjay Dixit, Andrew E. Epstein, Fermin C. Garcia, Edward P. Gerstenfeld, Mathew D. Hutchinson, David Lin, Vickas V. Patel, Michael P. Riley, Melissa R. Robinson, Wendy S. Tzou, Ralph J. Verdino, David J. Callans, Francis E. Marchlinski
Journal: Journal of the American College of Cardiology (2012)
Observations on copper associated protein in childhood liver disease.
Authors: J Evans, S P Newman, S Sherlock
Journal: Gut (1980)

Hepatic copper concentrations were compared with staining grades of copper associated protein (CAP) and histochemical copper in liver sections from 44 patients (one fetus, one pre-term infant, four term infants, eight normal children, 16 children with various liver diseases, and 14 patients with intrahepatic cholestasis of childhood (IHCC)). A similar comparative study of hepatic copper concentration with CAP and histochemical copper was performed in 21 patients with Wilson9s disease. CAP occurred in the fetus, pre-term infant, and term infants without liver disease. This suggests that CAP is a normal constituent of the hepatocyte and is not a consequence of liver disease or biliary obstruction. CAP was not seen when hepatic copper concentration was normal; it was absent in eight children with no evidence of liver disease, eight children with non-cirrhotic liver disease, and seven of eight children with cirrhosis. When hepatic copper concentration exceeded 4.0 mumol/g dry liver weight grade 2 or grade 3 staining for CAP and histochemical copper was found in the fetus, pre-term infant, infants, and IHCC. CAP was found in IHCC only in the presence of raised hepatic copper levels, supporting evidence of a relationship between copper and CAP. In 17 of 21 patients with Wilson9s disease hepatic copper concentrations exceeded 4 mumol/g. Positive staining for CAP was seen in seven of these patients being usually grade 1. CAP is a normal associated protein, present when hepatic copper concentrations are increased in normal liver cells. It is usually absent in hepatocytes from Wilson9s disease despite similar hepatic copper levels. CAP may represent material which protects the hepatocyte from the toxic effects of copper.